Terlipressin Acetate Patent Expiration

Terlipressin Acetate is Used for improving kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. It was first introduced by Mallinckrodt Pharmaceuticals Ireland Ltd in its drug Terlivaz on Sep 14, 2022.


Terlipressin Acetate Patents

Given below is the list of patents protecting Terlipressin Acetate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Terlivaz US10335452 Method of treating patients with hepatorenal syndrome type 1 Apr 05, 2037 Mallinckrodt Ireland


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Terlipressin Acetate's patents.

Given below is the list recent legal activities going on the following patents of Terlipressin Acetate.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 03 Jan, 2023 US10335452
Patent Issue Date Used in PTA Calculation 02 Jul, 2019 US10335452
Recordation of Patent Grant Mailed 02 Jul, 2019 US10335452
Email Notification 13 Jun, 2019 US10335452
Issue Notification Mailed 12 Jun, 2019 US10335452
Dispatch to FDC 05 Jun, 2019 US10335452
Application Is Considered Ready for Issue 22 May, 2019 US10335452
Issue Fee Payment Verified 21 May, 2019 US10335452
Issue Fee Payment Received 21 May, 2019 US10335452
Electronic Review 25 Feb, 2019 US10335452



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳